CY1105085T1 - Ενωσεις τυπου ν-φορμυλο υδροξυλαμινης ως αναστολεις της pdf - Google Patents

Ενωσεις τυπου ν-φορμυλο υδροξυλαμινης ως αναστολεις της pdf

Info

Publication number
CY1105085T1
CY1105085T1 CY20061100965T CY061100965T CY1105085T1 CY 1105085 T1 CY1105085 T1 CY 1105085T1 CY 20061100965 T CY20061100965 T CY 20061100965T CY 061100965 T CY061100965 T CY 061100965T CY 1105085 T1 CY1105085 T1 CY 1105085T1
Authority
CY
Cyprus
Prior art keywords
hydroxylamine compounds
alkanes
formyl hydroxylamine
pdf inhibitors
treatment
Prior art date
Application number
CY20061100965T
Other languages
English (en)
Inventor
Dinesh V. Patel
Zhengyu Yuan
Rakesh K. Jain
Salvador Garcia Alvarez
Jeffrey Jacobs
Original Assignee
Vicuron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vicuron Pharmaceuticals, Inc. filed Critical Vicuron Pharmaceuticals, Inc.
Publication of CY1105085T1 publication Critical patent/CY1105085T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Ν-[01-οξο-2-αλκυλο-3-(Ν-υδροξυφορμαμιδο)-προπυλο]-(καρβονυλαμινο-αρυλο ή ετεροαρυλο)-αζακυκλο 4-7 αλκάνια ή θειαζακυκλο 4-7 αλκάνια ή ιμιδαζακυκλο 4-7 αλκάνια με ενδιαφέρουσες ιδιότητες, π.χ. στην αντιμετώπιση ή πρόληψη διαταραχών που δύνανται να αντιμετωπιστούν μέσω αναστολέων πεπτιδυλο αποφορμυλάσης όπως στην αντιμετώπιση βακτηριακών μολύνσεων.
CY20061100965T 2001-06-15 2006-07-12 Ενωσεις τυπου ν-φορμυλο υδροξυλαμινης ως αναστολεις της pdf CY1105085T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29841901P 2001-06-15 2001-06-15
US36031302P 2002-02-27 2002-02-27
PCT/EP2002/006604 WO2002102790A1 (en) 2001-06-15 2002-06-14 N-formyl hydroxylamine compounds as inhibitors of pdf

Publications (1)

Publication Number Publication Date
CY1105085T1 true CY1105085T1 (el) 2009-11-04

Family

ID=26970649

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061100965T CY1105085T1 (el) 2001-06-15 2006-07-12 Ενωσεις τυπου ν-φορμυλο υδροξυλαμινης ως αναστολεις της pdf

Country Status (31)

Country Link
US (1) US7148242B2 (el)
EP (1) EP1401828B1 (el)
JP (1) JP4361365B2 (el)
KR (2) KR100589544B1 (el)
CN (1) CN1511152A (el)
AR (1) AR036053A1 (el)
AT (1) ATE323081T1 (el)
AU (1) AU2002321062B2 (el)
BR (1) BR0210377A (el)
CA (1) CA2448526A1 (el)
CO (1) CO5640131A2 (el)
CY (1) CY1105085T1 (el)
CZ (1) CZ20033388A3 (el)
DE (1) DE60210612T2 (el)
DK (1) DK1401828T3 (el)
ES (1) ES2262824T3 (el)
HK (1) HK1064370A1 (el)
HU (1) HUP0400208A3 (el)
IL (1) IL158770A0 (el)
MX (1) MXPA03011628A (el)
MY (1) MY138619A (el)
NO (1) NO327420B1 (el)
NZ (1) NZ529489A (el)
PE (1) PE20030100A1 (el)
PL (1) PL364476A1 (el)
PT (1) PT1401828E (el)
RU (1) RU2325386C2 (el)
SI (1) SI1401828T1 (el)
SK (1) SK15242003A3 (el)
WO (1) WO2002102790A1 (el)
ZA (1) ZA200308379B (el)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE360014T1 (de) * 2001-06-15 2007-05-15 Vicuron Pharm Inc Bicyclische pyrrolidinverbindungen
GB0208579D0 (en) * 2002-04-13 2002-05-22 British Biotech Pharm Antibacterial agents
WO2004026824A1 (en) 2002-09-19 2004-04-01 Novartis Ag Process for preparing intermediates
BRPI0407448A (pt) * 2003-02-21 2006-01-31 Novartis Ag Processo quìmico
TW200427458A (en) * 2003-04-02 2004-12-16 Novartis Ag Crystalline N-formyl hydroxylamine compounds
BRPI0411921A (pt) * 2003-06-26 2006-08-15 Novartis Ag processo para preparar intermediários úteis para preparar determinadas hidroxilaminas de n-formila antibacterianas
KR100527624B1 (ko) * 2003-08-21 2005-11-22 한기종 질소에 포밀기를 갖는 아민유도체의 새로운 제조방법
WO2006002896A1 (en) * 2004-06-30 2006-01-12 Novartis Ag Method for increasing the susceptibility of peptide deformylase inhibitors by using efflux pump inhibitors
JP2008520686A (ja) 2004-11-17 2008-06-19 スミスクライン・ビーチャム・コーポレイション 新規な抗菌化合物の使用
GT200600196A (es) * 2005-05-23 2007-01-15 Compuestos n-formil de hidroxilamina
DE102005026231A1 (de) * 2005-06-07 2006-12-14 Origenis Ag Peptid-Deformylase (PDF) Inhibitoren 3
JP2008545765A (ja) * 2005-06-07 2008-12-18 ノバルティス アクチエンゲゼルシャフト ペプチドデホルミラーゼ（ｐｄｆ）阻害剤４
SG133452A1 (en) * 2005-12-30 2007-07-30 Novartis Ag Peptide deformylase inhibitors for treatment of mycobacterial and other parasitic diseases
EP1994027A2 (en) * 2006-03-03 2008-11-26 Novartis AG N-formyl hydroxylamine compounds
CN101328155B (zh) * 2007-06-20 2010-11-03 上海医药工业研究院 噁唑烷衍生物及其制备方法和应用
CN101434570B (zh) * 2007-11-16 2011-02-02 上海医药工业研究院 吡咯烷衍生物及其制备方法和应用
CN101584694B (zh) * 2009-06-15 2011-01-12 华东师范大学 含2,5-二氢吡咯的肽脱甲酰基酶抑制剂及合成方法
BR112012008147A2 (pt) * 2009-09-04 2016-03-01 Novartis Ag compostos heteroarílicos como inibidores da quinase
SG183192A1 (en) 2010-03-10 2012-09-27 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases
JP5825086B2 (ja) 2011-12-19 2015-12-02 住友化学株式会社 α−置換−β−アミノ酸エステル誘導体不斉加水分解酵素
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
ES2876974T3 (es) 2015-04-07 2021-11-15 Novartis Ag Combinación de terapia con receptor de antígeno quimérico y derivados de amino pirimidina
WO2017193924A1 (zh) * 2016-05-11 2017-11-16 如东瑞恩医药科技有限公司 螺三元环、螺五元环类肽脱甲酰基酶抑制剂及其在抗菌和抗肿瘤中的应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4052511A (en) 1976-02-13 1977-10-04 E. R. Squibb & Sons, Inc. Carboxyacylproline derivatives
US4311705A (en) 1980-10-06 1982-01-19 E. R. Squibb & Sons, Inc. Carboxyalkanoyl and hydroxycarbamoylalkanoyl derivatives of substituted prolines
US4321383A (en) 1980-11-24 1982-03-23 E. R. Squibb & Sons, Inc. Heterobicyclo intermediates
US4303662A (en) 1980-11-24 1981-12-01 E. R. Squibb & Sons, Inc. Carboxyacyl, mercapto and acylmercapto derivatives of heterobicyclo compounds
JPS6188884A (ja) 1984-10-04 1986-05-07 Sankyo Co Ltd エンケフアリナ−ゼｂ阻害物質およびその製法
US4599361A (en) 1985-09-10 1986-07-08 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
DK77487A (da) 1986-03-11 1987-09-12 Hoffmann La Roche Hydroxylaminderivater
FR2609289B1 (fr) 1987-01-06 1991-03-29 Bellon Labor Sa Roger Nouveaux composes a activite d'inhibiteurs de collagenase, procede pour les preparer et compositions pharmaceutiques contenant ces composes
US5128346A (en) 1987-09-21 1992-07-07 Abbott Laboratories Derivatives of D-glutamic acid and D-aspartic acid
EP0334244A3 (en) 1988-03-25 1991-05-29 The Procter & Gamble Company Bradykinin antagonist peptides
GB8827308D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
GB8919251D0 (en) 1989-08-24 1989-10-04 British Bio Technology Compounds
GB8921326D0 (en) 1989-09-21 1989-11-08 Beecham Group Plc Novel treatment
US5268384A (en) 1990-11-21 1993-12-07 Galardy Richard E Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors
AU652596B2 (en) 1990-12-03 1994-09-01 Celltech Limited Peptidyl derivatives
CA2058797A1 (en) 1991-02-01 1992-08-02 Michael John Broadhurst Amino acid derivatives
GB9102635D0 (en) 1991-02-07 1991-03-27 British Bio Technology Compounds
IT1245712B (it) 1991-04-09 1994-10-14 Boehringer Mannheim Italia Ammine eterocicliche utili terapia dell'asma e dell'infiammazione delle vie aeree
AU2228292A (en) 1991-06-14 1993-01-12 Research Corporation Technologies, Inc. Peptide derivatives of collagenase inhibitor
US5256657A (en) 1991-08-19 1993-10-26 Sterling Winthrop, Inc. Succinamide derivative matrix-metalloprotease inhibitors
JPH05125029A (ja) 1991-11-06 1993-05-21 Yamanouchi Pharmaceut Co Ltd 新規なアミド化合物又はその塩
DE69230916T2 (de) 1991-11-08 2000-12-14 Sankyo Co Piperazin Derivate als Collagenase Inhibitoren
ATE150452T1 (de) 1992-04-07 1997-04-15 British Biotech Pharm Hydroxamsäure enthaltende collagenase-inhibitoren und cytokinaktivitätsinhibitoren
GB9211706D0 (en) 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
GB9211707D0 (en) 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
US5318964A (en) 1992-06-11 1994-06-07 Hoffmann-La Roche Inc. Hydroxamic derivatives and pharmaceutical compositions
GB9215665D0 (en) 1992-07-23 1992-09-09 British Bio Technology Compounds
US5552419A (en) 1993-01-06 1996-09-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
TW290541B (el) 1993-03-18 1996-11-11 Otsuka Pharma Factory Inc
CA2139128A1 (en) 1993-04-27 1994-11-10 Celltech Therapeutics Limited Peptidyl derivatives as metalloproteinase inhibitors
GB9308695D0 (en) 1993-04-27 1993-06-09 Celltech Ltd Peptidyl derivatives
GB9501737D0 (en) 1994-04-25 1995-03-22 Hoffmann La Roche Hydroxamic acid derivatives
GB9411598D0 (en) 1994-06-09 1994-08-03 Hoffmann La Roche Hydroxamic acid derivatives
GB9502858D0 (en) 1995-02-14 1995-04-05 British Biotech Pharm Novel use of matrix metalloproteinase inhibitors
GB9504084D0 (en) 1995-03-01 1995-04-19 British Biotech Pharm Synthesis of carboxylic and hydroxamic acid derivatives
FR2733750B1 (fr) 1995-05-03 1997-06-13 Synthelabo Derives de l'acide gamma-oxo-alpha-(phenylmethyl)-5,6- dihydro-4h-thieno(3,4-c)pyrrole-5-butanoique, leur preparation et leur application en therapeutique
EP0939632B1 (en) 1996-02-23 2005-10-05 Eli Lilly And Company NON-PEPTIDYL VASOPRESSIN V1a ANTAGONISTS
TW448172B (en) 1996-03-08 2001-08-01 Pharmacia & Upjohn Co Llc Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation
GB9613547D0 (en) 1996-06-27 1996-08-28 Pharmacia Spa Matrix metalloproteinase inhibitors
AUPO721997A0 (en) 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
JP2001500533A (ja) 1997-07-10 2001-01-16 フアルマシア・エ・アツプジヨン・エツセ・ピー・アー マトリックスメタロプロテイナーゼ・インヒビター
CN1298299A (zh) 1998-02-07 2001-06-06 英国生物技术药物有限公司 抗菌剂

Also Published As

Publication number Publication date
RU2325386C2 (ru) 2008-05-27
KR20040010721A (ko) 2004-01-31
CA2448526A1 (en) 2002-12-27
KR100589544B1 (ko) 2006-06-15
AU2002321062B2 (en) 2006-02-02
DE60210612D1 (de) 2006-05-24
NO20035571L (no) 2004-02-16
US7148242B2 (en) 2006-12-12
DK1401828T3 (da) 2006-07-31
EP1401828A1 (en) 2004-03-31
WO2002102790A1 (en) 2002-12-27
NZ529489A (en) 2005-10-28
HUP0400208A3 (en) 2008-10-28
KR20060014083A (ko) 2006-02-14
HK1064370A1 (en) 2005-01-28
JP4361365B2 (ja) 2009-11-11
PE20030100A1 (es) 2003-03-28
SI1401828T1 (sl) 2006-10-31
PT1401828E (pt) 2006-08-31
EP1401828B1 (en) 2006-04-12
RU2003137565A (ru) 2005-05-27
IL158770A0 (en) 2004-05-12
MY138619A (en) 2009-07-31
MXPA03011628A (es) 2005-03-07
JP2005502606A (ja) 2005-01-27
AR036053A1 (es) 2004-08-04
SK15242003A3 (sk) 2004-07-07
HUP0400208A2 (hu) 2004-06-28
ES2262824T3 (es) 2006-12-01
DE60210612T2 (de) 2006-09-21
CZ20033388A3 (en) 2004-03-17
ZA200308379B (en) 2004-05-21
CO5640131A2 (es) 2006-05-31
US20030045479A1 (en) 2003-03-06
NO20035571D0 (no) 2003-12-12
NO327420B1 (no) 2009-06-29
BR0210377A (pt) 2004-08-10
CN1511152A (zh) 2004-07-07
PL364476A1 (en) 2004-12-13
ATE323081T1 (de) 2006-04-15

Similar Documents

Publication Publication Date Title
CY1105085T1 (el) Ενωσεις τυπου ν-φορμυλο υδροξυλαμινης ως αναστολεις της pdf
EP3569601A3 (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
CY1107688T1 (el) Δικυκλικες ενωσεις πυρρολιδινης
CY2014028I1 (el) Ενωσεις, φαρμακοτεχνικες μορφες και μεθοδοι θεραπειας ή αποτροπhς ροδοχρωμης ακμης
CY1110742T1 (el) Αναστολεις ινδαζολης, βενζισοξαζολης, και βενζισοθειαζολης
NO331013B1 (no) Nye forbindelser som er anti-inflammasjons, immunomodulerende og anti-proliferative midler, anvendelse av forbindelsene samt farmasoytisk preparat
EA200970738A1 (ru) Ингибиторы активности akt
CY1112947T1 (el) Παραγωγα πυρρολης καταλληλα για την θεραπεια πολλαπλασιαστικων ασθενειων
NO20082414L (no) Inhibitorer av AKT-aktivitet
ATE368031T1 (de) Neue gamma secretase inhibitoren
NO20084912L (no) Bisykliske derivater som CETP-inhibitorer
NO20081016L (no) Nye 1-aryl-3-azabicyklo(3.1.0)heksaner, fremstilling og bruk for å behandle nevropsykiatriske lidelser
CY1113314T1 (el) (3-αρυλ-πιπεραζιν-1-υλ) παραγωγα της 6,7-διαλκοξυκιναζολινης, 6,7-διαλκοξυφθαλαζινης και 6,7-διαλκοξυϊσοκινολινης
NO20055741L (no) Nye kjemiske forbindelser
NO20060392L (no) Kombinasjon av SRC kinase inhibitorer kemoterapeutiske midler for behandling av proliferative sykdommer
ECSP045021A (es) Terapia de combinacion para el tratamiento del cancer
BRPI0416268A (pt) composições de delta-9-thc e métodos para o tratamento de sintomas associados à esclerose múltipla
NO20062832L (no) Nye salicylanilider
ATE403433T1 (de) Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen
BRPI0718469A2 (pt) Uso de um antagonista de interleucina 1 (il-1), método para tratar, inibir, ou melhorar pseudogota, uso de um ou mais agentes terapêuticos, e, produto.
NO20093542L (no) Inhibering av tumormetastase ved hjelp av anti-neuropilin 2-antistoffer
TW200706534A (en) N-formyl hydroxylamine compounds
NO20064793L (no) Anvendelse av N-(2-arylpropionyl) sulfonamider for behandling av ryggmargskade.
DK1362045T3 (da) 2-Thio-substituerede imidazolderivater og deres anvendelse inden for farmacien
CY1110796T1 (el) Παραγωγα μορφολινης ως αναστολεις επαναπροσληψης νορεπινεφρινης